Skip to content

Amin Rostami‐hodjegan

2 papers in the library · 157 citations · publishing 2006-2008

Papers

Sort Most recent Most cited

The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans

Journal of Clinical Psychopharmacology September 12, 2008 Brian O’Mathúna, Magı́ Farré, Amin Rostami‐hodjegan et al. 68 citations

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a widely abused substituted amphetamine. MDMA is predominantly O-demethylenated in humans by cytochrome P450 isoforms 2D6 and 1A2 (CYP2D6 and CYP CYP1A2, respectively). MDMA is also a mechanism-based inhibitor of CYP2D6. A controlled clinical trial was conducted in 15 healthy male subjects whereby a probe drug, dextromethorphan (DEX), was...

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA

Journal of Psychopharmacology May 20, 2006 Jiansong Yang, Masoud Jamei, Amir Heydari et al. 89 citations

The aim of this study was to model the in vivo kinetic consequences of mechanism-based inhibition (MBI) of CYP2D6 by 3,4 methylenedioxymethamphetamine (MDMA, ecstasy). A model with physiologically-based components of drug metabolism was developed, taking account of change in the hepatic content of active CYP2D6 due to MBI by MDMA. Based on the in vitro information, plasma concentration time...